Esperion Therapeutics Inc (ESPR)
R&D to Revenue
11.22%
Quarterly · Period ending:
ESPR R&D to Revenue
Latest reported11.22%period ending
Latest reported11.22%period ending
ESPR Quarterly R&D/Revenue (406335.70% → 11.22%)
Latest values, visible window
High-resolution chart · PNG
ESPR r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 11.2204% | |
| 8.2673% | |
| 16.185% | |
| 8.7856% | |
| 19.3199% | |
| 15.8827% | |
| 20.1367% | |
| 15.5227% | |
| 9.731% | |
| 55.014% | |
| 43.8194% | |
| 85.7015% | |
| 128.986% | |
| 175.5394% | |
| 153.5458% | |
| 172.1352% | |
| 129.1092% | |
| 179.313% | |
| 175.7998% | |
| 61.669% | |
| 350.3886% | |
| 435.4015% | |
| 920.5061% | |
| 16.485% | |
| 1,885.9783% | |
| 3,893.4827% | |
| 4,921.6106% | |
| 4,357.2301% | |
| 31.8445% | |
| 26.8184% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 539,100% | |
| 560,400% | |
| 492,200% | |
| 670,100% | |
| 610,300% | |
| 406,335.7% |